REDUCTION OF LIPOPROTEIN(A) BY LDL-APHERESIS USING A DEXTRAN SULFATE CELLULOSE COLUMN IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

被引:39
作者
KOIZUMI, J
KOIZUMI, I
UNO, Y
INAZU, A
KAJINAMI, K
HARAKI, T
YAGI, K
KAMON, N
MIYAMOTO, S
TAKEGOSHI, T
MABUCHI, H
TAKEDA, R
TANI, N
TAKADA, S
机构
[1] HOKURIKU HOSP,DEPT INTERNAL MED,KANAZAWA 921,JAPAN
[2] FUKUI PREFECTURAL HOSP,DEPT INTERNAL MED,FUKUI 910,JAPAN
[3] KANEGAFUCHI CHEM IND,CENT RES LAB,KOBE,JAPAN
关键词
D O I
10.1016/0021-9150(93)90068-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lipoprotein(a) (Lp(a)) was eliminated by LDL-apheresis using a dextran sulfate cellulose column in 3 homozygous and 10 heterozygous familial hypercholesterolemic patients. Immediately after LDL-apheresis by the LA- 1 5 system (continuous LDL apheresis), there were significant reductions in Lp(a) concentrations (28.6 +/- 11.8 mg/dl (mean +/- S.E.) to 9.6 +/- 5.6 mg/dl (P < 0.01)), and in LDL-cholesterol concentrations (156 +/- 32 mg/dl to 48 +/- 18 mg/dl (P < 0.01)). Immediately following LDL-apheresis, Lp(a) and LDL-cholesterol were reduced by 67.4% +/- 11.6% and 68.3% +/- 11.8%, respectively. The removal of Lp(a) paralleled that of LDL-cholesterol. The reduced levels of Lp(a) nearly returned to baseline within 7 days. In 6 of the heterozygous FH patients the rates of recovery of LDL cholesterol and Lp(a) were calculated, according to Apstein's equation after discontinuing lipid altering drug treatment for 4 weeks. Mean constant k values of LDL cholesterol and Lp(a) were 0.354 (range : 0.136-0.752) and 0.427 (range 0.112-0.933), respectively. The average concentration during the 7 days following LDL-apheresis was calculated. Average reductions were 28% in LDL cholesterol and 18% in Lp(a). Pravastatin treatment, which continued for 4 weeks, significantly decreased LDL cholesterol (P < 0.01); however, before LDL-apheresis pravastatin treatment significantly increased Lp(a) levels (P < 0.05) in a small number (n = 6) of the FH patients, who had been regularly treated with LDL-apheresis. These results suggest that LDL-apheresis using the dextran sulfate cellulose column is an effective treatment to reduce levels of serum Lp(a) and LDL proportionally. This therapy may be of value in the prevention and regression of coronary artery disease in FH patients.
引用
收藏
页码:65 / 74
页数:10
相关论文
共 50 条
  • [21] LDL-APHERESIS IN PATIENTS WITH HYPERCHOLESTEROLEMIA TYPE-II-A
    TAUCHERT, M
    STOFFEL, W
    BODE, C
    BORBERG, H
    OETTE, K
    FUCHS, M
    HOMBACH, V
    ARTERIOSCLEROSIS, 1983, 3 (05): : A485 - A485
  • [22] LDL-apheresis in combination with treatment of seven familial hypercholesterolemia - Methods and results
    vonBaeyer, H
    Schwerdtfeger, R
    Schartl, M
    MEDIZINISCHE WELT, 1996, 47 (02): : 74 - 78
  • [23] Long-term effect of LDL-apheresis on familial hypercholesterolemia homozygotes
    Yamamoto, A
    Kawaguchi, A
    Harada-Shiba, M
    LIPOPROTEIN METABOLISM AND ATHEROGENESIS, 2000, : 19 - 25
  • [24] Intravascular ultrasound analysis of coronary plaque regression by LDL-apheresis in patients with familial hypercholesterolemia: The LDL-apheresis coronary morphology and reserve trial (LACMART)
    Matsuzaki, M
    Hiramori, K
    Kitabatake, A
    Hishida, H
    Fujii, T
    Sakuma, I
    Fukami, K
    Honda, T
    Ogawa, H
    CIRCULATION, 1999, 100 (18) : 82 - 82
  • [25] Cytokines profile in serum of homozygous familial hypercholesterolemia is changed by LDL-apheresis
    Stefanutti, C.
    Vivenzio, A.
    Di Giacomo, S.
    Ferraro, P. M.
    CYTOKINE, 2011, 55 (02) : 245 - 250
  • [26] Angiotensin receptor antagonists during dextran sulfate LDL-apheresis are safe
    Sinzinger, H
    Chehne, F
    Ferlitsch, A
    Oguogho, A
    THROMBOSIS RESEARCH, 2000, 100 (01) : 43 - 46
  • [27] TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA BY PLASMA-EXCHANGE AND LDL-APHERESIS
    PALCOUX, JB
    MEYER, M
    JOUANEL, P
    TRIDON, A
    VANLIEFERINGHEN, P
    CARLA, H
    MALPUECH, G
    TRANSFUSION SCIENCE, 1993, 14 (04): : 423 - 427
  • [28] COMBINATION THERAPY WITH LDL-APHERESIS AND MEVINOLIN FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (FH)
    BARBIR, M
    OKABAYSHI, K
    TRAYNER, I
    HARTNELL, G
    THOMPSON, G
    ATHEROSCLEROSIS, 1987, 68 (03) : 272 - 272
  • [29] LDL-Apheresis in Homozygous LDL-Receptor-Defective Familial Hypercholesterolemia: The Munich Experience
    Keller, Christiane
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (05) : 21 - 26
  • [30] A NEW LOW-DENSITY-LIPOPROTEIN APHERESIS SYSTEM USING 2 DEXTRAN SULFATE CELLULOSE COLUMNS IN AN AUTOMATED COLUMN REGENERATING UNIT (LDL CONTINUOUS APHERESIS)
    MABUCHI, H
    MICHISHITA, I
    TAKEDA, M
    FUJITA, H
    KOIZUMI, J
    TAKEDA, R
    TAKADA, S
    OONISHI, M
    ATHEROSCLEROSIS, 1987, 68 (1-2) : 19 - 25